# Pharmacogenomics in Autism Treatment

> **NCT00584701** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 49 (actual)

## Conditions studied

- Autism

## Interventions

- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00584701
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2012-07-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00584701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00584701, "Pharmacogenomics in Autism Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00584701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*